SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 11, 2016
BONE BIOLOGICS CORPORATION
(Exact name of registrant as specified in its charter)
or other jurisdiction
321 Columbus Ave.
|(Address of principal executive offices)||(Zip Code)|
Registrant’s telephone number, including area code: (732) 661-2224
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|[ ]||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|[ ]||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|[ ]||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|[ ]||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
|Item 5.02.||Department of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.|
In order to assist the Board in its efforts to reduce its size from nine (9) to a more manageable seven (7) members, Mr. George A. Oram, the least tenured member, at the request of the Board, has agreed to resign, with regret, effective March 11, 2016. To the Company’s knowledge, the resignation of Mr. Oram was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: March 15, 2016||Bone Biologics Corporation|
|By:||/s/ STEPHEN R. LaNEVE|
|Name:||Stephen R. LaNeve|
|Title:||Chief Executive Officer|